●首页 加入收藏 网站地图 热点专题 网站搜索 [RSS订阅] [WAP访问]  
语言选择:
英语联盟 | www.enun.cn
英语学习 | 英语阅读 | 英语写作 | 英语听力 | 英语语法 | 综合口语 | 考试大全 | 英语四六 | 英语课堂 | 广播英语 | 行业英语 | 出国留学
品牌英语 | 实用英语 | 英文歌曲 | 影视英语 | 幽默笑话 | 英语游戏 | 儿童英语 | 英语翻译 | 英语讲演 | 求职简历 | 奥运英语 | 英文祝福
背景:#EDF0F5 #FAFBE6 #FFF2E2 #FDE6E0 #F3FFE1 #DAFAF3 #EAEAEF 默认  
阅读内容

Second Cervical Cancer Vaccine Ready for Market

[日期:2007-07-06]   [字体: ]
 
A second cervical cancer vaccine has passed a key clinical trial and its maker is seeking to use the vaccine in countries around the world. As VOA's Carol Pearson reports, more women may be able to use this new vaccine by drug giant GlaxoSmithKline than use the first cervical cancer vaccine, Gardisil.
 
When drug maker Merck made Gardisil available in 2006, it was the first vaccine designed to prevent cancer in humans, specifically cervical cancer.  Gardisil is recommended for girls and women ages nine to 25 before they become sexually active. 
 
But now a second vaccine, Cervarix, has proven effective in clinical trials for women up to the age of 45, including those who are sexually active. 

Dr. Gary Dubin oversaw clinical trials of Cervarix that involved more than 18,000 women from 14 countries across Europe, Asia, Latin and North America.

He says the results show Cervarix provides 100 percent protection against two major strains of the human papillomavirus, or HPV, which cause cervical cancer. 

"The reason this is important is that these two HPV types are responsible for about 70 percent of cervical cancers globally."

Dr. Levi Downs is an investigator in the Cervarix study at the University of Minnesota. He adds, "Secondly, and very important, they show us the vaccine is also effective against other HPV types that can cause cervix cancer.

Virtually 100 percent of women have the potential of receiving some benefit from this vaccine."

The studies also show Cervarix is effective even for women who previously had cancerous lesions, provided those lesions have been cleared.

More than half a million women around the world will be diagnosed with cervical cancer this year.  The disease will claim the lives of nearly 300,000 women. 

GlaxoSmithKline has initiated a study comparing Cervarix with Gardisil to see if one vaccine is more effective than the other. So far, no data is available.

But with the expected approval of Cervarix in many countries, women can add another weapon in their arsenal against the cancer-causing human papillomavirus.

   免责声明:本站信息仅供参考,版权和著作权归原作者所有! 如果您(作者)发现侵犯您的权益,请与我们联系:QQ-50662607,本站将立即删除!
 
阅读:

推荐 】 【 打印
相关新闻      
本文评论       全部评论
发表评论

点评: 字数
姓名:
内容查询

热门专题
 图片新闻